These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32841278)

  • 21. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
    Hu H; Miao XK; Li JY; Zhang XW; Xu JJ; Zhang JY; Zhou TX; Hu MN; Yang WL; Mou LY
    Eur J Pharmacol; 2020 May; 874():172961. PubMed ID: 32044322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET.
    Oh HN; Lee MH; Kim E; Kwak AW; Yoon G; Cho SS; Liu K; Chae JI; Shim JH
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32070026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer.
    Li X; Zhao X; Li C; Liu S; Yan F; Teng Y; Feng J; Miao D
    Hum Cell; 2019 Jul; 32(3):360-366. PubMed ID: 31020605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
    Emdad L; Lebedeva IV; Su ZZ; Gupta P; Sarkar D; Settleman J; Fisher PB
    J Cell Physiol; 2007 Feb; 210(2):549-59. PubMed ID: 17111370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
    Tang MC; Wu MY; Hwang MH; Chang YT; Huang HJ; Lin AM; Yang JC
    PLoS One; 2015; 10(3):e0119135. PubMed ID: 25807554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
    Li X; Fan XX; Jiang ZB; Loo WT; Yao XJ; Leung EL; Chow LW; Liu L
    Pharmacol Res; 2017 Jan; 115():45-55. PubMed ID: 27864022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
    Lai XY; Shi YM; Zhou MM
    Kaohsiung J Med Sci; 2023 Jul; 39(7):699-709. PubMed ID: 37057810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer cell‑specific anticancer effects of Coptis chinensis on gefitinib‑resistant lung cancer cells are mediated through the suppression of Mcl‑1 and Bcl‑2.
    Kim JH; Ko ES; Kim D; Park SH; Kim EJ; Rho J; Seo H; Kim MJ; Yang WM; Ha IJ; Park MJ; Lee JY
    Int J Oncol; 2020 Jun; 56(6):1540-1550. PubMed ID: 32236607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
    Van Schaeybroeck S; Kyula J; Kelly DM; Karaiskou-McCaul A; Stokesberry SA; Van Cutsem E; Longley DB; Johnston PG
    Mol Cancer Ther; 2006 May; 5(5):1154-65. PubMed ID: 16731747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiRNA-153-3p promotes gefitinib-sensitivity in non-small cell lung cancer by inhibiting ATG5 expression and autophagy.
    Zhang W; Dong YZ; Du X; Peng XN; Shen QM
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2444-2452. PubMed ID: 30964170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines.
    Terzuoli E; Costanza F; Ciccone V; Ziche M; Morbidelli L; Donnini S
    Prostaglandins Other Lipid Mediat; 2019 Aug; 143():106344. PubMed ID: 31207300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.